Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Brain and Nervous System
What is the purpose of this trial?
This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Ages18 years and older
- Trial withAlliance Cooperative Group
- Start Date10/27/2019
- End Date12/30/2021
- Last Updated10/29/2019
- Study HIC#2000026111